Table 2.

Association of Elevated MSI2 Expression with Clinical Features in Cancers

MSI2 Status	Cancer Type	Detection Method	Association
Increased expression	ALL49	qRT-PCR	Poor prognosis
	AML50,51	qRT-PCR	Poor prognosis
	Breast cancer37	Tissue microarray	Poor prognosis
	Pancreatic cancer19,36	qRT-PCR,19 IHC,19,36 WB19,36	Advanced stages,19,36 Tumor size,19 Poor prognosis,19 Differentiation,36 Lymph node metastasis36
	Colorectal cancer52	Tissue microarray, IHC	Depth of invasion, Lymph node metastasis, Distant metastasis, Advanced stage
	Liver cancer53,54	qRT-PCR,53 WB,53 IHC54	Chemoresistance,53 Poor prognosis54
	Lung cancer55	IHC	Poor prognosis
	Ovarian cancer56	Tissue microarray, IHC	Advanced stages
	Cervical cancer41,57	qRT-PCR,41,57 WB57	Lymph node metastasis,57 Advanced stages,57 Poor prognosis41,57
	Bladder cancer58	qRT-PCR, WB	Lymph node metastasis, Poor prognosis
	Gastric cancer59	IHC	Invasion depth, Lymph node metastasis, Degree of differentiation, Tumor size
	Glioblastoma60	IHC, WB	Malignancy
Reduced expression	TNBC23	IHC, qRT-PCR, RNA sequencing	Differentiation, Distant metastasis, Poor prognosis